Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Study Design: 203 obese patients (BMI 3040 kg/m) Randomized to tesofensine 0.25 mg, 0.5 mg, 1.0 mg, or placebo All groups received dietary counseling (mild energy restriction) Primary endpoint: change in body weight at 24 weeks Registered as NCT00394667 Key Results: The 0.5 mg dose produced 10.6% placebo-subtracted weight loss roughly double what existing anti-obesity drugs (sibutramine, orlistat) achieved at the time
Current concepts in age-related hearing loss: epidemiology and mechanistic pathways
Designed for individuals seeking daily nutritional support for cellular energy metabolism, antioxidant support, and everyday vitality.*
International Review of Cell and Molecular Biology, 347 , 191223
10.1158/1078-0432.Ccr-16-1789 Clin
Therefore, stopping the accumulation of FFAs from two directions is of vital importance in the prevention of liver steatosis
US$ 28.89
US$ 29.20
US$ 25.74
US$ 27.75
